The infectious consequences of rituximab addition to fludarabine-containing regimens [6]

Blood

Volumn 107, Issue 7, 2006, Pages 3013-3014

  Tam, Constantine S ^b   Seymour, John F ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; INFECTION RISK; LETTER; LYMPHOCYTE; LYMPHOCYTOPENIA; MONOTHERAPY; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN INTERACTION;

EID: 33645551195     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-10-4012     Document Type: Letter

References (10)

1. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538-1543.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
4. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
5. Morrison VA, Byrd JC, Peterson BL, Rai K, Larson RA. Adding rituximab to fludarabine therapy for patients with untreated Chronic Lymphocytic Leukemia does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) study 9712 [abstract]. Blood. 2003;102:440a. Abstract 1606.
6. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
7. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludaradine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2004;104:3064-3071.
8. McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance [abstract]. Proc Am Soc Clin Oncol. 2003;22:564. Abstract 2269.
9. Tam C, Seymour JF, Brown M, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica. 2005;90:700-702.
10. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906-2911.